If memantine is not helping, the next step is a clinician-led reassessment—not an abrupt stop or an automatic switch to a newer drug. The clinician should look for treatable causes of decline, confirm the dementia type and stage, and decide whether to continue, taper, or change treatment. Memantine is an NMDA-receptor antagonist approved for moderate-to-severe Alzheimer's dementia. It may ease symptoms, but it cannot stop or reverse the disease, according to the National Institute on Aging.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How can you tell whether memantine is helping?
- What should be checked before changing treatment?
- When does stopping memantine make sense?
- Are there other symptom treatments?
- Are lecanemab or donanemab the next step?
- What matters when medication benefit is limited?
How can you tell whether memantine is helping?
There may be no dramatic improvement. Because dementia can continue progressing during treatment, ongoing decline does not automatically prove that memantine provides no benefit. The practical question is whether it supports cognition, daily function, behavior, or overall stability enough to justify continuing it.
before an appointment, record specific changes over several weeks. Note whether the person needs more help dressing, eating, managing medications, communicating, sleeping, or staying calm. Also record side effects, missed doses, and when each change began; concrete examples are more useful than saying the medicine "does nothing.".
What should be checked before changing treatment?
A new or faster decline may come from something other than dementia progression. The National Institute on Aging's assessment guidance identifies medication effects, depression, delirium or infection, endocrine or metabolic disorders, and vitamin deficiency as possible causes of cognitive problems.
Ask the clinician to review: A sudden or unexplained change deserves prompt assessment. Finding a contributing condition can change the treatment plan even when the underlying dementia remains.
- Whether the original dementia diagnosis and current stage still fit.
- All prescription drugs, nonprescription products, and supplements.
- Changes in mood, alertness, sleep, appetite, mobility, or daily abilities.
- Whether doses are taken consistently.
- Whether testing is needed for infection, vitamin deficiency, or metabolic and endocrine problems.
When does stopping memantine make sense?
A 2022 Canadian consensus guideline says clinicians should consider discontinuation after more than 12 months when there has been no meaningful benefit. Other reasons include significant decline without another explanation, troublesome side effects, poor adherence, or severe or end-stage dementia.
Stopping should be treated as a monitored trial, not an irreversible decision. The Canadian consensus guideline generally recommends halving the dose every four weeks and restarting treatment if cognition, function, behavior, or overall condition worsens meaningfully after withdrawal. The prescriber should set the schedule and define what changes would trigger a restart.
Are there other symptom treatments?
Medication choices depend on the type and stage of dementia. Donepezil, rivastigmine, and galantamine are cholinesterase inhibitors used for symptoms of mild-to-moderate Alzheimer's disease.
A memantine-and-donepezil combination is approved for moderate-to-severe disease. These drugs are not interchangeable upgrades, and adding one does not guarantee improvement. A clinician must weigh previous treatment, side effects, adherence, dementia stage, and the outcomes that matter most—such as communication, personal care, agitation, or safe mobility.
Are lecanemab or donanemab the next step?
Usually not when someone already has moderate-to-severe dementia. Lecanemab and donanemab should be started only in people with Alzheimer's-related mild cognitive impairment or mild dementia after amyloid-beta pathology has been confirmed, as specified in the FDA labels for Leqembi and Kisunla. These treatments slow decline rather than restore lost abilities.
In donanemab's 76-week pivotal trial, the FDA reported a 2.92-point advantage over placebo on an integrated measure of cognition and daily function. They also require careful risk assessment and MRI monitoring because they can cause amyloid-related imaging abnormalities, or ARIA—brain swelling or bleeding visible on scans. Risk is higher in people with two copies of the APOE ε4 gene. For eligible Medicare patients, access also requires documented brain amyloid, follow-up care, and a clinician participating in a qualifying registry.
What matters when medication benefit is limited?
A treatment plan should cover more than memory scores. It should address home and driving safety, meaningful activities, physical and social activity, behavioral triggers, caregiver support, and opportunities for respite.
For distress or behavior changes, start by looking for practical contributors. Reduce noise and confusion, keep routines calm, and address hearing or vision problems before or alongside behavioral medication. Bring a written list of recent changes, side effects, missed doses, and care priorities to the next clinical review.
